Leukocyte activity in patients with ST-segment elevation acute myocardial infarction treated with anakinra - Test2 - elhamkhani - TriplyDB

Leukocyte activity in patients with ST-segment elevation acute myocardial infarction treated with anakinra

Leukocyte activity in patients with ST-segment elevation acute myocardial infarction treated with anakinra

http://www.wikidata.org/entity/Q34777497

about

Targeting danger-associated molecular patterns after myocardial infarction.P2X7 receptor inhibition attenuated sympathetic nerve sprouting after myocardial infarction via the NLRP3/IL-1β pathway.Anti-inflammatory drugs as promising cardiovascular treatments.Immunomodulatory interventions in myocardial infarction and heart failure: a systematic review of clinical trials and meta-analysis of IL-1 inhibition

P2860

Q38595544-C61EC08E-1C71-4710-A253-C51E04C0FB30 Q38805353-01F968F3-7F68-48F3-8B0E-88C912673CB0 Q39051784-A510B77A-DC7C-4D79-865A-9964F749C653 Q57162899-044AEDF1-85C8-49FD-8AC9-18085F74BBDA

P2860

Leukocyte activity in patients with ST-segment elevation acute myocardial infarction treated with anakinra

http://www.wikidata.org/entity/Q34777497

description

2014 nî lūn-bûn

@nan

2014 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Leukocyte activity in patients ...... farction treated with anakinra

@ast

Leukocyte activity in patients ...... farction treated with anakinra

@en

Leukocyte activity in patients ...... farction treated with anakinra

@nl

type

label

Leukocyte activity in patients ...... farction treated with anakinra

@ast

Leukocyte activity in patients ...... farction treated with anakinra

@en

Leukocyte activity in patients ...... farction treated with anakinra

@nl

prefLabel

Leukocyte activity in patients ...... farction treated with anakinra

@ast

Leukocyte activity in patients ...... farction treated with anakinra

@en

Leukocyte activity in patients ...... farction treated with anakinra

@nl

P1433

Q34777497-0D636D79-03C3-41CB-A613-1BCF119C8C88

P1476

Q34777497-6BDC7572-B16F-4DB8-B2DA-FC9225DBD355

P2093

Q34777497-1C574546-AC7D-4ABB-AE3F-7CDFBB18F9D6

Q34777497-2AF8DD1F-8F6D-4E6C-805A-387A9D8AAB5E

Q34777497-3DB161EC-A915-4C9E-A7DB-9DD56DC4D818

Q34777497-73FF7DCE-2C50-4E72-BA74-90218AA4FC8A

Q34777497-A2C69522-1851-4ED2-9AEA-8CCA03C52562

Q34777497-B29227F6-437A-4C23-B179-D15A25A02365

Q34777497-B5C7FA35-2EEC-4FC7-A054-CF27A809ED4E

Q34777497-BDE59EF5-B14F-44DB-B20E-DD653A2230EA

Q34777497-D73B7BAF-F23D-499B-9847-167B47AD8282

Q34777497-DCAABF0F-29A7-456F-9FBA-FA48E2C784C3

P2860

Q34777497-24831E8B-D5C4-426F-8257-F35B4AACF33B

Q34777497-3A27FBA4-5EF8-4441-9715-69CC472EFBE5

Q34777497-48473028-1E19-47C3-AF8E-174334A0BF90

Q34777497-5877D4EC-3195-45F5-9C0D-52E89DBBCDC4

Q34777497-5AA7D314-AD82-4935-9F29-5B5ACA98BD0F

Q34777497-68A554B7-EF86-43D5-A5AE-D3283B6E9EBC

Q34777497-80CE4A99-DEA0-4D92-B36D-1AD28BEFF416

Q34777497-827CE240-8E41-4F07-9C71-1A38A511C9E6

Q34777497-843E5BAA-91FC-4E0F-A111-0205FD175E28

Q34777497-A46A1275-3326-4B41-9005-414B510F6A65

P2888

Q34777497-A8036506-002F-4697-90F1-801093C9ED79

P304

Q34777497-CBF69D9D-11B4-4B03-B358-EB0A62F6C3C2

P31

Q34777497-27B869B6-AE07-42F0-BD7D-F6F848D78192

P356

Q34777497-BD51897B-E52A-4C51-AB46-30715192180E

P407

Q34777497-A263E8E7-4EB3-459C-8EA5-007A7EDAD8BF

P478

Q34777497-5D669872-6D43-4FFC-9F88-E3A674A79973

P50

Q34777497-4FDDC0AC-4060-4236-8352-17FE3EC0ADD0

P577

Q34777497-C969CE67-11EB-4960-9DBB-D5A2AB6AE0B1

P6179

Q34777497-C7973858-21D5-4778-932E-A013F1E3CC6E

P698

Q34777497-571130A5-A83E-4BEF-B981-188D65C545FB

P921

Q34777497-EC8E9B32-C573-4943-9B0F-3F492700DDEA

P932

Q34777497-DE0FE63E-83E6-4F88-BBE5-44B488D39FF8

P356

MOLMED.2014.00121

P1433

Molecular Medicine

P1476

Leukocyte activity in patients ...... farction treated with anakinra

@en

P2093

Amit Varma

http://www.w3.org/2001/XMLSchema#string

Antonio Abbate

http://www.w3.org/2001/XMLSchema#string

Benjamin W Van Tassell

http://www.w3.org/2001/XMLSchema#string

Chiara Sonnino

http://www.w3.org/2001/XMLSchema#string

Claudia Oddi

http://www.w3.org/2001/XMLSchema#string

George H Mueller

http://www.w3.org/2001/XMLSchema#string

Michael L Gambill

http://www.w3.org/2001/XMLSchema#string

Nayef A Abouzaki

http://www.w3.org/2001/XMLSchema#string

Raquel Appa Falcao

http://www.w3.org/2001/XMLSchema#string

Ryan D Melchior

http://www.w3.org/2001/XMLSchema#string

P2860

Interleukin-1 in the pathogenesis and treatment of inflammatory diseases

Safety of extended treatment with anakinra in patients with rheumatoid arthritis

Targeting interleukin-1 in heart disease

Enhanced interleukin-1 activity contributes to exercise intolerance in patients with systolic heart failure

Cardiac remodeling--concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling.

The inflammasome promotes adverse cardiac remodeling following acute myocardial infarction in the mouse.

Effects of gevokizumab on glycemia and inflammatory markers in type 2 diabetes

Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases.

Effects of interleukin-1 blockade with anakinra on adverse cardiac remodeling and heart failure after acute myocardial infarction [from the Virginia Commonwealth University-Anakinra Remodeling Trial (2) (VCU-ART2) pilot study].

Effects of interleukin-1 blockade with anakinra on aerobic exercise capacity in patients with heart failure and preserved ejection fraction (from the D-HART pilot study)

P2888

molmed.2014.00121

P304

486-489

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2119/MOLMED.2014.00121

http://www.w3.org/2001/XMLSchema#string

P407

P478

20

http://www.w3.org/2001/XMLSchema#string

P50

Charles A. Dinarello

P577

2014-11-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1068965677

http://www.w3.org/2001/XMLSchema#string

P698

25121719

http://www.w3.org/2001/XMLSchema#string

P921

P932

4277550

http://www.w3.org/2001/XMLSchema#string